Live attenuated vaccines against pertussis (Q38236200)

31 August 2017

title

Live attenuated vaccines against pertussis (English)

1 reference

31 August 2017

1 reference

Nathalie Mielcarek

0 references

Camille Locht

0 references

1 August 2014

1 reference

Expert Review of Vaccines

31 August 2017

published in

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

1147-1158

1 reference

How best to estimate the global burden of pertussis?

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

New pertussis vaccination approaches: en route to protect newborns?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Morbidity of pertussis in adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Duration of immunity against pertussis after natural infection or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Is adolescent pertussis vaccination preferable to natural booster infections?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Estimating the duration of pertussis immunity using epidemiological signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

The recurrence of whooping cough: possible implications for assessment of vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Bordetella pertussis, molecular pathogenesis under multiple aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Bordetella pertussis pathogenesis: current and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

The ins and outs of pertussis toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Immunoglobulin A-mediated protection against Bordetella pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

O antigen protects Bordetella parapertussis from complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Human infections associated with Bordetella bronchiseptica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Trained immunity: a memory for innate host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

A small jab - a big effect: nonspecific immunomodulation by vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Sex differences in the vaccine-specific and non-targeted effects of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Vaccines against mucosal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Live bacterial vectors for intranasal delivery of protective antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

The Number Needed to Vaccinate to Prevent Infant Pertussis Hospitalization and Death Through Parent Cocoon Immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.942222

10.1586/14760584.2014.942222

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference